2025-07-08 - Analysis Report
Okay, here's a report analyzing Transmedics Group Inc. (TMDX) based on the provided data.

**Report: Transmedics Group Inc. (TMDX) Analysis**

**1. Performance Overview vs. S&P 500 (VOO)**

*   **Ticker:** TMDX
*   **Company Description:** Transmedics Group Inc. is a medical technology company focused on developing and delivering innovative organ care system (OCS) technology for transplantation.

**Key Performance Metrics:**

*   **TMDX Cumulative Return:** 242.47%
*   **VOO (S&P 500) Cumulative Return:** 67.71%
*   **Absolute Divergence:** 174.76% (TMDX significantly outperformed VOO)
*   **Relative Divergence:** 67.5 (Suggests TMDX's outperformance is in the upper-middle range of its historical divergence from VOO).

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha  | Beta | Cap(B) |
|------------|--------|-------|--------|------|--------|
| 2019-2021  | -4.0%  | 63.4% | -52.0% | 0.0  | 0.6    |
| 2020-2022  | 140.0% | 68.3% | 138.0% | 0.1  | 2.0    |
| 2021-2023  | 95.0%  | 69.4% | 77.0%  | 0.2  | 2.6    |
| 2022-2024  | 147.0% | 82.8% | 121.0% | 0.2  | 2.0    |
| 2023-2025  | 124.0% | 82.8% | 76.0%  | 0.5  | 4.2    |

**Analysis:**

*   **Strong Outperformance:** TMDX has significantly outperformed the S&P 500 (VOO) over the entire period.
*   **High Volatility:**  The high MDD (Maximum Drawdown) values across all periods indicate substantial price volatility.  Investors should be prepared for potential significant drops in value.
*   **Positive Alpha:** The positive alpha values suggest that TMDX has consistently generated returns above what would be expected based on its beta.
*   **Beta:** The beta values indicate that TMDX's price is not closely correlated with the S&P 500.
* **Cap(B):** 최근 증가하는 추세이며, 이는 회사가 시장에서 점점 더 인정받고 있다는 긍정적인 신호일 수 있습니다.

**2. Recent Stock Price Movement**

*   **Current Price:** 129.19
*   **Last Market Data:** Price: 125.22, Previous Close: 129.19, Change: -3.07 (Indicates a recent price drop)
*   **5-Day Moving Average:** 130.20
*   **20-Day Moving Average:** 133.96
*   **60-Day Moving Average:** 114.07

**Analysis:**

*   **Price Decline:** The current price is below both the 5-day and 20-day moving averages, suggesting a recent downward trend.  The price drop in the last market session further reinforces this.
*   **Positive Long-Term Trend:** The 60-day moving average is significantly lower than the current price, indicating a positive trend over the past couple of months.

**3. Technical Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.33 (Low Risk)
*   **RSI:** 35.79 (Approaching Oversold Territory)
*   **PPO:** -1.38 (Negative Value Indicates a Downtrend)
*   **Hybrid Signal:** cash_69%_Sell 0.7% of holdings (4 shares - Caution - MRI:0.35)
*   **20-Day Relative Divergence Change:** -2.3 (Short-Term Decline)
*   **Expected Return:** 49.4% (Long-Term, vs. S&P 500)

**Analysis:**

*   **Conflicting Signals:**  The MRI indicates low risk, while the RSI is approaching oversold territory.  The PPO confirms a downtrend. The Hybrid Signal is cautioning against further investment with a high cash allocation suggesting defensive strategy.
*   **Recent Price Drop Impact:** The last market price change confirms a recent price drop, which likely contributes to the negative short-term divergence change.
*   **High Expected Return:**  The 49.4% expected return is very attractive, suggesting significant long-term potential relative to the S&P 500. However, this should be considered alongside the company's volatility and risk profile.

**4. Recent News & Significant Events**

*   **Volatility:** Stock has shown notable volatility due to recent news, earnings reports, or executive actions.
*   **Analyst Discussions:** Analysts are discussing the company's recent performance and outlook.
*   **Business Developments:** The company has recently made headlines due to major business developments, regulatory changes, or market events.
*   **Risk/Opportunity Balance:** Market experts are highlighting both risks and opportunities.

**Analysis:**

*   **Active News Cycle:** TMDX is currently experiencing a period of heightened news flow and market attention.  This can lead to increased price volatility.
*   **Importance of Monitoring:** Investors should closely monitor news and company announcements.

**5. Recent Earnings Analysis**

| Date       | EPS  | Expected EPS |
|------------|------|--------------|
| 2025-05-08 | 0.70 | 0.29         |
| 2025-02-27 | 0.19 | 0.22         |
| 2024-10-28 | 0.12 | 0.29         |
| 2024-07-31 | 0.35 | 0.21         |
| 2024-04-30 | 0.35 | 0.03256      |

**Analysis:**

*   **Earnings Beat:** TMDX has significantly exceeded EPS expectations in the most recent quarter (2025-05-08).
*   **Mixed Performance:**  Prior to the latest quarter, the company had a mixed record of beating or missing EPS expectations.
*   **Positive Trend:** There's a positive trend of consistently exceeding the expected EPS in recent quarters.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-03-31 | $0.14B  | 61.47%        |
| 2024-12-31 | $0.12B  | 59.21%        |
| 2024-09-30 | $0.11B  | 55.94%        |
| 2024-06-30 | $0.11B  | 60.59%        |
| 2024-03-31 | $0.10B  | 61.91%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE    |
|------------|---------|--------|
| 2025-03-31 | $0.27B  | 9.64%  |
| 2024-12-31 | $0.23B  | 3.00%  |
| 2024-09-30 | $0.21B  | 2.01%  |
| 2024-06-30 | $0.19B  | 6.42%  |
| 2024-03-31 | $0.16B  | 7.65%  |

**Analysis:**

*   **Revenue Growth:**  Revenue has been steadily increasing over the past five quarters.
*   **High Profit Margin:** The company maintains a very high profit margin (above 55%), indicating strong pricing power and efficient operations.
*   **Equity Growth:** Equity has been steadily increasing, demonstrating financial strength.
*   **Strong ROE:** A ROE of 9.64% in the most recent quarter is very strong. The ROE has been volatile, but trending up again.

**7. Overall Summary**

Transmedics Group Inc. (TMDX) presents a mixed picture for investors.

**Positives:**

*   **Significant Historical Outperformance:**  TMDX has significantly outperformed the S&P 500 in the past.
*   **High Growth Potential:** The expected return is very attractive.
*   **Strong Financials:**  Revenue, profit margins, equity, and ROE are generally strong and trending in the right direction.
*   **Recent Earnings Beat:** TMDX significantly exceeded EPS expectations in the most recent quarter.

**Negatives:**

*   **High Volatility:** The stock has a history of high price volatility, as evidenced by the large MDD values.
*   **Recent Downtrend:** The current price is below short-term moving averages and has experienced a recent price drop.
*   **Conflicting Signals:** Technical indicators provide mixed signals.
* **Hybrid signal Suggests reducing the holding.**

**Conclusion:**

TMDX appears to be a high-growth, high-risk investment. Its strong financials, history of outperformance, and recent earnings beat are encouraging. However, investors should be aware of the stock's volatility and the recent downward price trend. The recent news and analyst discussions indicate that the company is undergoing significant developments, which could further impact the stock's performance. Cautious monitoring and potentially a defensive strategy, as suggested by the Hybrid Signal, might be warranted.
